advisorsecurities master

ANVSAnnovis Bio, Inc.

CSNew York Stock Exchange (XNYS)·USD

Identity

Security key
11751
Ticker
ANVS
Type
CSCommon Stock
Exchange
New York Stock Exchange(XNYS)
Venue group
NYSE
Operating MIC
XNYS
Market
stocks
Locale
us
Currency
USD
Listed
2020-01-29
Round lot
100
Active
Yes
Last seen in a load
2026-08-14 20:49
Vendor updated
2026-08-13 06:09
Ticker root / suffix
ANVS

Detail

Enriched 2026-08-14 20:47

Market cap
$76,575,362.4
Shares outstanding (class)
34,646,868
Shares outstanding (weighted)
42,541,868
SIC
2834 PHARMACEUTICAL PREPARATIONS
Employees
7
Location
MALVERN, PA
Description

Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.

Market cap and share counts drift.

Funds holding this security

Identifiers

Classification

Fund data